At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 355 enrolled
Drug / intervention
13-valent Pneumococcal Conjugate Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Open-label Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Older Infants and Children Who Are Naive to Previous Vaccination With Pneumococcal Conjugate Vaccine.
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Mar 27, 2007·Updated Aug 15, 2012
In Brief
A Phase 3 clinical trial evaluating 13-valent Pneumococcal Conjugate Vaccine for Pneumococcal Infections. Completed, enrolled 355 participants across 9 sites.
Detailed Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent Pneumococcal conjugate vaccine (13vPnC) in older infants and children who have not previously been immunized with Pneumococcal vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infections
CountriesPoland
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartJul 2007
Primary CompletionMar 2008
TodayJul 2026
First PostedMar 27, 2007
Enrollment StartJul 1, 2007
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.3 years ago
Interventions
13-valent Pneumococcal Conjugate Vaccinebiological